Search results
-
ESMO 2023 – not so fast, Welireg
ESMO 2023 – not so fast, Welireg Full …
- 10/22/2023 - 16:00 -
ESMO 2023 – GSK sets up Pfizer battle in B7-H4
ESMO 2023 – GSK sets up Pfizer battle in B7-H4 … inhibitor 6 Ph1 China study in solid tumours ESMO 2023: 29% ORR across TNBC pts; 27-33% ORR at target … Monomethyl auristatin E 4 Ph1 in solid tumours ESMO 2023 abstract: responses in breast (7/25), ovarian …
- 12/20/2023 - 14:07 -
ESMO 2023 – sabestomig has it all to do in TIM-3
ESMO 2023 – sabestomig has it all to do in TIM-3 …
- 10/21/2023 - 18:04 -
ESMO 2023 – Amgen’s Steap1 project spurs cautious optimism
ESMO 2023 – Amgen’s Steap1 project spurs cautious …
- 10/21/2023 - 15:55 -
ESMO 2023 – Amgen keeps tarlatamab filing plans under wraps
ESMO 2023 – Amgen keeps tarlatamab filing plans under … DLL3 positivity 40% ORR with 10mg dose (40/100 pts) at ESMO 2023, responses seen regardless of DLL3 expression; …
- 10/21/2023 - 10:50 -
ESMO 2023 – Perla gives Jemperli combos more backing
ESMO 2023 – Perla gives Jemperli combos more backing …
- 10/21/2023 - 11:10 -
After failing to get Seagen Merck turns to Daiichi
… TROP2 4 Tropion-Lung01 & Tropion-Breast01 data at ESMO 2023 Astra paid $1bn up front, $1bn due in …
- 10/21/2023 - 15:55 -
ESMO 2023 – Jiangsu Hengrui sets a low bar in KRAS G12D inhibition
ESMO 2023 – Jiangsu Hengrui sets a low bar in KRAS G12D …
- 10/18/2023 - 16:33 -
ESMO 2023 – duelling PD-1 drugs
ESMO 2023 – duelling PD-1 drugs Quick …
- 10/18/2023 - 15:52 -
ESMO 2023 – tarlatamab hits the target for Amgen
ESMO 2023 – tarlatamab hits the target for Amgen … T-cell engager Ph2 Dellphi-301 3L SCLC (data at ESMO 2023) BI 764532 Boehringer Ingelheim … Ph1 SCLC & neuroendocrine tumours (focus on NETs at ESMO 2023) HPN328 Harpoon Therapeutics …
- 10/18/2023 - 15:54
